The Effect of 4-Aminopyridine on Clinical Signs in Multiple Sclerosis
Ann Neurol 32:123-130, vanDiemen,H.A.M.,et al, 1992
Angelman Syndrome: Clinical Profile
J Child Neurol 7:270-280, Zori,R.T.,et al, 1992
4-Aminopyridine in Multiple Sclerosis:Prolonged Administration
Neurol 41:1344-1348, Stefoski,D.,et al, 1991
Orally Administered 4-Aminopyridine Improves Clinical Signs in Multiple Sclerosis
Ann Neurol 27:186-192, Davis,F.A.,et al, 1990
Atherosclerosis:Current Concepts on Pathogenesis and Interventional Therapies
Ann Neurol 26:3-12, Yatsu,F.M.&Fisher,M., 1989
4-Aminopyridine Improves Clinical Signs in Multiple Sclerosis
Ann Neurol 21:71-77, Stefoski,D.,et al, 1987
Clinical & Biochemical Correlates of Bradyphrenia in Parkinson's Disease
Neurol 37:1130-1134, Mayeux,R.,et al, 1987
Prophylaxis of Atherosclerosis with Marine Omega-3 Fatty Acids, A Comprehensive Study
Ann Int Med 107:890-899, VonSchacky,C., 1987
Benign Versive or Circling Epilepsy with Bilateral 3-Cps Spike- & -Wave Discharges in Late Childhood
Ann Neurol 19:301-303, Gastaut,H.,et al, 1986
The Clinical Syndrome of Striatal Dopamine Deficiency, Parkinsonism Induced by MPTP
NEJM 312:1418-1421, Burns,R.S.,et al, 1985
Treatment with Oral 4-aminopyridine in Disorders of Neuromuscular Transmission
Neurol 31:265-271, Murray,N.M.F.,et al, 1981
Memory Impairment in Korsakoff's Psychosis:A Correlation with Brain Noradrenergic Activity
Science 202:905-907, McEntee,W.J.,et al, 1978
4-Aminopyridine-A New Drug Tested in the Treatment of Eaton-Lambert Syndrome
JNNP 40:1109, Lundh,H.,et al, 1977